4640 Results

People

  1. Saltz
    Saltz
  2. O'Reilly
    O'Reilly
  3. Abou-Alfa
    Abou-Alfa
  4. Kelsen
    Kelsen
  5. Ilson
    Ilson
  6. Kemeny
    Kemeny
  7. Janjigian
    Janjigian
  8. Reidy
    Reidy
  9. Jarnagin
    Jarnagin
  10. D'Angelica
    D'Angelica

Groups

  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)
  7. Epidemiology and Biostatistics (828)
  8. GSK Faculty (793)
  9. Department of Pathology and Laboratory Medicine (723)
  10. Biostatistics Service (661)
  1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03)
    Meeting Abstract

    Janjigian, Y. Y.; Viglianti, N.; Liu, F.; Mendoza-Naranjo, A.; Croydon, L.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase II study of infigratinib in previously treated advanced/metastatic cholangiocarcinoma with FGFR gene fusions/alterations
    Meeting Abstract

    Javle, M. M.; Kelley, R. K.; Springfeld, C.; Abou-Alfa, G. K.; Macarulla, T.; Tanasanvimon, S.; Goyal, L.; Borbath, I.; Bitzer, M.; Yong, W. P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement
    Meeting Abstract

    Javle, M. M.; Roychowdhury, S.; Kelley, R. K.; Sadeghi, S.; Macarulla, T.; Waldschmidt, D. T.; Goyal, L.; Borbath, I.; El-Khoueiry, A. B.; Yong, W. P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer
    Meeting Abstract

    Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202
    Meeting Abstract

    Geyer, S. M.; Mahoney, M. R.; Asmis, T. R.; Hall, N.; Karovic, S.; Knopp, M. V.; Kumthekar, P.; Nixon, A. B.; O'Reilly, E. M.; Schwartz, L. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT 'basket' trial
    Meeting Abstract

    Harding, J. J.; Cleary, J. M.; Quinn, D. I.; Braña, I.; Moreno, V.; Borad, M. J.; Loi, S.; Spanggaard, I.; Park, H.; Ford, J. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC)
    Meeting Abstract

    El Dika, I. H.; Geyer, S. M.; Nixon, A. B.; Innocenti, F.; Shi, Q.; Jacobson, S. B.; Yaqubie, A.; Lopez, J. C.; Huang, B. H.; Tang, Y. W.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative science from CALGB 80802 (Alliance)
    Meeting Abstract

    Dercle, L.; Geyer, S. M.; Nixon, A. B.; Innocenti, F.; Shi, Q.; Jacobson, S. B.; Luk, L.; Liu, A.; Yang, H.; Wen, Y.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer
    Meeting Abstract

    Desai, J.; Fakih, M.; Pedersen, K. S.; Hong, Y. S.; Segal, N. H.; Allen, S.; Bailey, L.; Lenain, C.; Lu, D.; Sayyed, P. Z.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Randomized phase II trial of olaparib + pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) mutations: SWOG S2001
    Meeting Abstract

    Chung, V.; Guthrie, K. A.; Pishvaian, M. J.; Lowy, A. M.; Chiorean, E. G.; Duong, M. T.; O'Reilly, E. M.; Philip, P. A.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save